Stanley Hirsch
Direktor/Vorstandsmitglied bei MATRICELF LTD
Profil
Stanley Hirsch is currently the Chief Executive Officer at FuturaGene, Inc. and a Director at FuturaGene Ltd.
and Matricelf Ltd.
He previously served as the Chief Executive Officer at CBD Technologies, Inc. and as Chairman at VYNE Pharmaceuticals Ltd., OWC Pharmaceutical Research Corp., and One World Cannabis Ltd.
He was also a Director at Menlo Therapeutics, Inc. and General Manager at Portman Pharmaceuticals, Inc. Hirsch holds a doctorate degree from the University of Oxford and an undergraduate degree from the University of Cape Town.
Aktive Positionen von Stanley Hirsch
| Unternehmen | Position | Beginn |
|---|---|---|
| MATRICELF LTD | Direktor/Vorstandsmitglied | 27.07.2022 |
FuturaGene Ltd.
 FuturaGene Ltd. BiotechnologyHealth Technology FuturaGene Ltd. researches and develops plant genetic for global biofuel, forestry and agricultural markets. The firm operates on research, development and commercialization of technologies that provide solutions for agriculture in a changing planet. The company is headquartered in London, the United Kingdom. | Direktor/Vorstandsmitglied | 15.08.2007 |
FuturaGene, Inc.
 FuturaGene, Inc. Other Metals/MineralsNon-Energy Minerals FuturaGene, Inc. operates as an agricultural biotechnology firm. It researches and delivers agronomic traits that improve and protect yield for forestry, biofuels, biopower, and agriculture. The company was founded in March 2001 and is headquartered in Lafayette, IN. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Stanley Hirsch
| Unternehmen | Position | Ende |
|---|---|---|
| VYNE THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 09.04.2020 |
| OWC PHARMACEUTICAL RESEARCH CORP. | Vorsitzender | 12.03.2020 |
One World Cannabis Ltd.
 One World Cannabis Ltd. Pharmaceuticals: MajorHealth Technology Part of OWC Pharmaceutical Research Corp., One World Cannabis Ltd. develops cannabis-based medical products. The company is based in Petach Tikva, Israel. Zvi Riterband has been the CEO of the Israeli company since 2020. | Vorsitzender | 12.03.2020 |
VYNE Pharmaceuticals Ltd.
 VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | Vorsitzender | 09.03.2020 |
| Portman Pharmaceuticals, Inc. | Corporate Officer/Principal | - |
Ausbildung von Stanley Hirsch
| University of Oxford | Doctorate Degree |
| University of Cape Town | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| OWC PHARMACEUTICAL RESEARCH CORP. | Miscellaneous |
| MATRICELF LTD | Health Technology |
| Private Unternehmen | 7 |
|---|---|
VYNE Pharmaceuticals Ltd.
VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | Health Technology |
Menlo Therapeutics, Inc.
 Menlo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Bridgewater, CA. | Health Technology |
FuturaGene Ltd.
FuturaGene Ltd. BiotechnologyHealth Technology FuturaGene Ltd. researches and develops plant genetic for global biofuel, forestry and agricultural markets. The firm operates on research, development and commercialization of technologies that provide solutions for agriculture in a changing planet. The company is headquartered in London, the United Kingdom. | Health Technology |
FuturaGene, Inc.
FuturaGene, Inc. Other Metals/MineralsNon-Energy Minerals FuturaGene, Inc. operates as an agricultural biotechnology firm. It researches and delivers agronomic traits that improve and protect yield for forestry, biofuels, biopower, and agriculture. The company was founded in March 2001 and is headquartered in Lafayette, IN. | Non-Energy Minerals |
CBD Technologies, Inc.
 CBD Technologies, Inc. TextilesProcess Industries Part of FuturaGene Ltd., CBD Technologies, Inc. provides biotechnology for forest improvement and the development of biologically-based, clean processes for paper manufacturing. The company is based in Bergenfield, NJ. The company was founded by Jonathan Joels, Oded Shoseyov. CBD Technologies was acquired by FuturaGene Ltd. on December 20, 2006 for $4.28 million. | Process Industries |
| Portman Pharmaceuticals, Inc. | |
One World Cannabis Ltd.
One World Cannabis Ltd. Pharmaceuticals: MajorHealth Technology Part of OWC Pharmaceutical Research Corp., One World Cannabis Ltd. develops cannabis-based medical products. The company is based in Petach Tikva, Israel. Zvi Riterband has been the CEO of the Israeli company since 2020. | Health Technology |
